DailyIQ
|
Sector:HealthcareAll sectors
Last updated 21 minutes ago

MCK·McKesson Corporation

$.
+. (+.%)
After Hours
High
$810.00
Open
$793.22
Market Cap
94.36B
52W High
$999.00
Low
$791.18
P. Close
$805.72
P/E
19.82
52W Low
$637.00
Fwd P/E
16.01
DailyIQ Est.
$969.55
Technical Score (1D)
55
BUY
News Sentiment
53
MIXED
McKesson’s CEO sold a sizable block of shares under a pre‑arranged trading plan, a move that may signal management’s view of the company’s near‑term prospects. The sale coincided with the appointment of a new Chief Strategy Officer after the retirement of a long‑time executive, indicating a shift in how the firm will prioritize its pharmaceutical, medical‑supply, and related‑services businesses. The company also updated its outlook and revised growth targets, suggesting a more aggressive or re‑aligned revenue trajectory. Together, the insider sale and leadership change raise questions about whether the new strategy chief will be able to deliver the revised guidance or whether the targets are overly optimistic. Over the next 1–10 trading days, investors should watch for any early signs of the new CSO’s priorities, such as changes in supplier contracts or investment in digital logistics. The market will also be attentive to how the updated growth targets compare to the company’s historical performance and analyst expectations. A key watch item is the company’s upcoming earnings report, which will test the feasibility of the new outlook. Additionally, any further leadership moves or strategic initiatives announced in the interim could confirm or undermine confidence in the new direction. Finally, analysts will monitor whether the insider sale is followed by additional share purchases or sales, which could reinforce or dampen the perceived sentiment behind the leadership changes.
Earnings Summary
McKesson Corporation, a global leader in healthcare services, distributes pharmaceuticals—including branded, generic, and specialty drugs—to pharmacies and healthcare providers worldwide while also offering technology and business solutions that support oncology practices and pharmacies; its Prescription Technology Solutions segment connects stakeholders to improve patient access and affordability, and it supplies medical‑surgical products to a broad range of facilities. In the most recent reporting cycle, McKesson posted EPS of $8.03 in Q4 2024, beating the $7.99 estimate, and $10.12 in Q1 2025, again surpassing the $9.83 estimate; the company continued this trend with $8.26 in Q2 2025 versus an $8.15 estimate, $9.86 in Q3 2025 versus a $9.05 estimate, and $11.69 in Q4 2026 versus an $11.68 estimate, underscoring a consistent pattern of earnings surprises across five consecutive quarters. Revenue mirrored this stability, rising from $95.29 billion in Q4 2024 to $90.82 billion in Q1 2025, then climbing to $97.83 billion in Q2 2025, $103.15 billion in Q3 2025, and $96.30 billion in Q4 2026, reflecting a mix of growth and modest declines that have not eroded the company’s overall upward trajectory. Historically, McKesson has maintained a streak of EPS growth while occasionally experiencing revenue volatility, yet it has consistently outperformed analyst expectations, reinforcing investor confidence in its cost‑control initiatives and margin expansion. Recent news highlights heightened investor interest, a price‑target upgrade from $850 to $860 by Evercore ISI, and expectations of a potential earnings beat in the upcoming August 5, 2026 report, all of which point to market optimism around the company’s specialty pharmacy and wholesale segments; analysts also emphasize the importance of monitoring pricing power, contract renewals, and regulatory impacts on margins. Looking ahead, investors should watch for guidance on operating margins, supply‑chain cost management, and the trajectory of specialty pharmacy growth, as these factors will be key to sustaining McKesson’s earnings momentum and validating the upgraded margin assumptions.

EPS

EstBeatMiss
$7.44$8.64$9.84$11.04$12.24Q4'24Q1'25Q2'25Q3'25Q4'26Q1'27
QtrEstActual+/−
Q1'27$9.62 - -
Q4'26$11.68$11.69+0.1%
Q3'25$9.05$9.86+8.9%
Q2'25$8.15$8.26+1.4%
Q1'25$9.83$10.12+3.0%
Q4'24$7.99$8.03+0.5%

Revenue

EstBeatMiss
$88.7B$93.3B$97.9B$102.6B$107.2BQ4'24Q1'25Q2'25Q3'25Q4'26Q1'27
QtrEstActual+/−
Q1'27$105.0B - -
Q4'26$102.4B$96.3B-5.9%
Q3'25 - $103.2B -
Q2'25 - $97.8B -
Q1'25 - $90.8B -
Q4'24 - $95.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MCK Stock Snapshot

MCK is currently trading at $806.05, giving McKesson Corporation a market cap of 94.36B and a P/E ratio of 19.8. Today's range spans $791.18–$810.00, with shares opening at $793.22 and moving up $0.33 (0.0%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 53/100.

Over the past year MCK has traded between $637.00 and $999.00 - the current price is +26.5% off the 52-week low and -19.3% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $941.40 (range $812.00–$1065.00), implying upside of +16.8%.

The setup for McKesson Corporation (MCK) is neither bullish nor bearish - it's patient. Score: 55/100 (HOLD). Sentiment: neutral (53/100). Price: $806.05 (in the middle of its 52-week range in $637.00–$999.00). The current P/E ratio stands at 19.8. A large-cap with 94.36B in Healthcare market cap in a neutral technical phase is exactly where position-sizing decisions get made before the next trend emerges.

In neutral phases, large-cap Healthcare names like MCK are often where sector rotation debates play out quietly — at 94.36B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (53/100) at $806.05 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.